Laura Puzniak

Pfizer, Inc.

La Jolla, CA

United States

SCHOLARLY PAPERS

4

DOWNLOADS
Rank 33,207

SSRN RANKINGS

Top 33,207

in Total Papers Downloads

2,925

SSRN CITATIONS

4

CROSSREF CITATIONS

0

Scholarly Papers (4)

1.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 18 Jan 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 2,112 (14,336)

Abstract:

Loading...

omicron, effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, kaiser

2.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 30 Jun 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 386 (146,759)
Citation 1

Abstract:

Loading...

BA.2, BA.1, omicron, effectiveness, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, Kaiser Permanente, real-world

3.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 384 (147,599)
Citation 5

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

4.

Risk Factors for Long Covid in a United States Prospective Longitudinal Community-Based Cohort

Number of pages: 51 Posted: 24 Apr 2024
City University of New York (CUNY) - Institute for Implementation Science in Population Health, City University of New York, City University of New York, City University of New York (CUNY) - Institute for Implementation Science in Population Health, City University of New York, affiliation not provided to SSRN, Pfizer, Inc., Pfizer, Inc., City University of New York, City University of New York, Pfizer, Inc. and City University of New York (CUNY) - Institute for Implementation Science in Population Health
Downloads 43 (774,781)

Abstract:

Loading...

Long COVID, COVID-19 vaccine, Quality of Life, Poor Physical Health Days, Risk Factors, Post COVID-19 Conditions, Post acute sequalae of COVID-19